Navigation Links
Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
Date:10/6/2009

rements and activities mentioned above, and assuming that no events occur which could cause further delay.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha- 2b. Helix is listed on the TSX and FSE under the symbol "HBP" and the OTCQX International Market under the symbol "HXBPF".

For further information contact:

    Investor Relations                 Media Relations
    Robert Flamm, Ph.D.                Ian Stone
    Russo Partners LLC                 Russo Partners LLC
    Tel: (212) 845-4226                Tel: (619) 814-3510
    Email:
    robert.flamm@russopartnersllc.com  Fax: (619) 955-5318
    www.russopartnersllc.com           Email: ian.stone@russopartnersllc.com

Forward-Looking Statements and Risks

This News Release contains certain forward-looking statements and forward-looking information, within the meaning of applicable securities laws, regarding the Company's development programs for Topical Interferon Alpha-2b and L-DOS47, including the Company's expected timing of anticipated IND filings in the United States, of completing the minimum required number of patients for the pharmacokinetic study in Germany, of the completion date for the AGW trial, and of the completion of necessary batch manufacturing and stability testing. Other forward-looking statements and information relate to, among other things, the Company's plans to
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
4. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
5. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
6. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
7. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... SAN FRANCISCO , Oct. 30, 2014  Nektar ... financial results for the third quarter ended September 30, ... of U.S.-based financial markets. Howard Robin , president ... to review the results beginning at 5:00 p.m. Eastern ... The press release and a live audio-only Webcast of ...
(Date:10/30/2014)... 30, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... third quarter 2014 financial results on Wednesday, November 5, ... Company,s management will hold a conference call at 7:30 ... is 8:30 p.m., Beijing Time on November 6, 2014, ...
(Date:10/30/2014)... 2014  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced an upcoming presentation highlighting ... aldoxorubicin.  The presentation, titled, "Drug Conjugates Bind Covalently ... by Sant P. Chawla , M.D., F.R.A.C.P., ... investigator of the Company,s ongoing global, pivotal Phase ...
Breaking Medicine Technology:Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2China Biologic to Report Third Quarter 2014 Financial Results 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4
(Date:10/30/2014)... Tanaka and her research group at the DFG Research ... at the TU Dresden (CRTD) demonstrated for the first ... spinal cord in three dimensions from mouse embryonic stem ... dorsal interneurons along the dorsal/ventral axis was observed., This ... " Stem Cell Reports " on 30.10.2014 ., ...
(Date:10/30/2014)... Don Allred Insurance, a leading provider of home, ... Carolina residents, is excited to announce the Grand Opening ... The new branch has been up and running since ... facets of the insurance selection process from quote comparison ... couldn’t be happier with the timing of this Grand ...
(Date:10/30/2014)... October 30, 2014 Radio listeners who ... questions about the impact of traditional radio commercials and ... most likely to influence a purchasing decision. , Those ... 525 consumers conducted by radio marketing company CRN International. ... isolating the results of respondents who indicated they have ...
(Date:10/30/2014)... Dr. Joseph Furlin MD, a certified obstetrician and gynecologist, has ... GYN in Melrose Park, IL and OB GYN ... about each of the care services and practice areas that ... and Spanish. The navigation of the website is easy ... Dr. Furlin’s patients with important information regarding his care methods ...
(Date:10/30/2014)... The human brain is often overlooked ... to help maintain better mental health, according to Dr. ... Lose Your Memory in 100 Ways’ for just that ... conflicting attitudes to help keep the reader constantly thinking. ... must decipher the hidden logic within. , “If you ...
Breaking Medicine News(10 mins):Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:Allred Insurance Satellite Office Grand Opening 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2
... YORK, Nov. 1 Fibromyalgia is the most ... affecting more than,six million Americans. But, findings from ... (NFA) show there is still much to be,learned ... the general public shows nearly half (45%) of ...
... Nov. 1 Always Best Care Senior,Services has expanded ... Service, and Personal Response Company, is proud,to announce seniors ... Senior,Services for outstanding care. For over a decade, a ... a sincere concern for the betterment of,life that goes ...
... Medicare plans in 90 cities will,be recognized ... their 2008 medical,and Part D prescription drug benefits ... were selected from over 200 Medicare Advantage,managed care ... HealthMetrix Research Inc. and MedicareNewsWatch.com. According,to HealthMetrix Research ...
... the current issue of Clinical Pharmacology & Therapeutics, ... Bioethics and Johns Hopkins Berman Institute of Bioethics ... vaccine debate, and its effects on ethical and ... was a major achievement for cervical cancer prevention ...
... Medical School (UMMS) will investigate the causes of type ... Research Foundation (JDRF) and The Iacocca Foundation. The grants, ... the UMMS Heat Shock Protein Consortium. Directed by Aldo ... of Medicine and professor of medicine and molecular medicine, ...
... 100th year of advancing cancer research, the American Association ... America, Europe, and Asia. The AACR has teamed ... for Science, Technology and Research (A*STAR) to hold the ... in Singapore: the AACR Centennial Conference on Translational Cancer ...
Cached Medicine News:Health News:Medialink Features: The Painful Truth About Fibromyalgia 2Health News:Announcing Always Best Care Senior Services Expansion Into Cleveland, Ohio 2Health News:HealthMetrix Research Selects 2008 Medicare Advantage Plans for Best Overall Benefit Value 2Health News:HealthMetrix Research Selects 2008 Medicare Advantage Plans for Best Overall Benefit Value 3Health News:HealthMetrix Research Selects 2008 Medicare Advantage Plans for Best Overall Benefit Value 4Health News:A missed shot: The failure of HPV vaccination state requirements 2Health News:A missed shot: The failure of HPV vaccination state requirements 3Health News:UMass Consortium awarded $300,000 from Juvenile Diabetes Research Foundation and Iacocca Foundation 2Health News:Emerging therapies with a focus on Asian populations mark the AACR Centennial Conference 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: